Gilead re­jigs HIV im­munother­a­py pact, grabs a stake in biotech part­ner

Back in No­vem­ber, im­munother­a­py play­er Hookipa told in­vestors about a twist in its big col­lab­o­ra­tion with Gilead: The biotech gi­ant de­cid­ed not to move for­ward with an HIV pro­gram “ac­cord­ing to cur­rent terms,” spark­ing dis­cus­sions about a new, re­vised pact.

Al­most four months lat­er, the com­pa­nies have reached a deal.

Gilead, which had agreed to foot the R&D bill for a joint re­search phase un­der the orig­i­nal terms draft­ed in 2018, now wants Hookipa to use “com­mer­cial­ly rea­son­ably ef­forts to fur­ther de­vel­op its HIV pro­gram can­di­date” through the com­ple­tion of a Phase Ib clin­i­cal tri­al. Once they reach that point, Gilead has the ex­clu­sive right to take back the de­vel­op­ment rights.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.